Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The ENVB news feed on Stock Titan aggregates company-issued press releases and other public updates so readers can follow how Enveric describes the progress of its pipeline, intellectual property estate, and capital markets activity.
Recent news from Enveric highlights several recurring themes. The company frequently reports on patent issuances and notices of allowance from the United States Patent and Trademark Office, including patents covering fused heterocyclic mescaline derivatives and N‑heterocycle substituted tryptamine derivatives within its EVM301 and EVM401 series. These announcements emphasize Enveric’s efforts to expand its portfolio of neuroplastogenic, non-hallucinogenic molecules and to strengthen composition of matter protection for potential treatments of neuropsychiatric and addiction disorders.
Another key category of ENVB news involves pipeline and preclinical development for the lead candidate EB‑003. Company updates have discussed preclinical models in post-traumatic stress disorder, dose range finding studies, chemistry and manufacturing work, and interactions with the U.S. Food and Drug Administration related to a planned Investigational New Drug submission. These items provide insight into how Enveric portrays the advancement of EB‑003 toward potential first-in-human studies.
Enveric also issues news related to financing and listing matters, such as warrant exercise inducement transactions, gross proceeds from warrant exercises, and actions taken in connection with Nasdaq listing requirements, including a reverse stock split. For investors and observers, these releases give context on how the company funds its operations and addresses exchange compliance.
By reviewing ENVB news on Stock Titan, readers can monitor Enveric’s own descriptions of its scientific progress, patent estate, financing transactions, and corporate developments over time. Investors who follow early-stage biotechnology companies may choose to consult these updates alongside the company’s SEC filings for a fuller view of the risks and plans Enveric outlines in its public communications.
Enveric Biosciences (NASDAQ: ENVB) has priced its underwritten public offering of 20 million shares of common stock, paired with warrants for an additional 20 million shares, at a combined price of $0.50 per share. The offering is expected to close by February 15, 2022, aiming to raise gross proceeds of approximately $10 million for general corporate purposes. A.G.P./Alliance Global Partners is the sole book-running manager for this offering, which includes a 45-day option for the underwriter to purchase an additional 3 million shares.
Enveric Biosciences announced the development of EV104a and EV104b, new molecular conjugates aimed at treating Osteoarthritis (OA) and other pain conditions. These conjugates combine cannabidiol (CBD) with celecoxib to improve pharmacokinetics and efficacy while reducing side effects. Pre-clinical testing is ongoing, and a provisional patent has been filed. CEO Joseph Tucker emphasized the need for better OA treatments, as current therapies are inadequate. This initiative positions Enveric to potentially enhance treatment options for patients suffering from OA-related pain.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on mental health and oncology treatments, announced that CEO Dr. Joseph Tucker will participate in two upcoming investor conferences. The first is Citi's Psychedelic Drug Call Series on February 8, 2022, at 10:00 a.m. ET, followed by the Aegis Capital Corp. Virtual Conference on February 25, 2022, at 3:00 p.m. ET. Enveric specializes in leveraging psychedelic-derived molecules and synthetic cannabinoids for innovative therapeutic solutions targeting conditions like cancer-related distress and PTSD.
Enveric Biosciences (NASDAQ: ENVB) released a shareholder letter reflecting on 2021 and outlining plans for 2022. The company raised $25 million and acquired MagicMed Industries. In 2021, they filed 15 patent applications and established a drug discovery platform. Looking forward, Enveric aims to progress its drug development pipeline, focusing on a Phase II clinical trial for Cancer Related Distress using EVM-101 and continuing to develop product candidates through AI-driven discovery. As of September 30, 2021, Enveric had $21 million in cash, supporting their business strategy.
Enveric Biosciences (NASDAQ: ENVB) has announced that CEO Dr. Joseph Tucker will participate in the H.C. Wainwright BioConnect Conference scheduled for January 10-13, 2022. His corporate presentation will be available on-demand starting January 10. The company focuses on developing innovative mental health and oncology treatments using psychedelic-derived molecules and synthetic cannabinoids. Enveric aims to address conditions like cancer-related distress and PTSD, supporting drug development for millions of patients worldwide.
Enveric Biosciences (NASDAQ: ENVB) has appointed Dr. Bob Dagher as Chief Medical Officer, effective immediately. With over 20 years of clinical development experience in neurology and psychiatry, Dr. Dagher aims to advance the company's psychedelic-derived and synthetic cannabinoid treatments. His prior roles include Chief Medical Officer at WCG MedAvante-ProPhase and Cadent Therapeutics. Dr. Robert Wilkins, the previous CMO, stepped down on November 29, 2021. CEO Joseph Tucker emphasizes the importance of Dr. Dagher's expertise in driving Enveric's drug development programs.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on mental health and oncology, announced that Dr. Joseph Tucker, CEO, will present at the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021. The presentation will be available on-demand starting at 7:00 a.m. ET. This conference aims to showcase innovative treatments derived from psychedelics and synthetic cannabinoids, with Enveric's research targeting conditions like cancer-related distress and PTSD. Attendees can register to watch and schedule one-on-one meetings with management.
Enveric Biosciences (NASDAQ: ENVB) announced promising preclinical results for its product EV102, aimed at treating radiodermatitis in cancer patients. In rodent models, EV102 demonstrated a nearly 50% reduction in skin redness and overall dermatitis severity, as well as a decrease in symptom duration. These findings are critical as radiodermatitis affects up to 95% of radiation therapy patients. The company plans to advance EV102 to a Phase I clinical study in the second half of 2022, underpinning its commitment to improving the quality of life for cancer patients.
Enveric Biosciences (NASDAQ: ENVB) announced its inclusion in the AdvisorShares Psychedelics ETF (PSIL), which targets biotech and pharma companies focusing on psychedelic treatments. This milestone is seen as a validation of Enveric's innovative platform for developing psychedelic and cannabinoid medicines aimed at addressing mental health issues and oncology treatments. CEO Joseph Tucker emphasized that this recognition will enhance their visibility within the investment community.
Enveric Biosciences (NASDAQ: ENVB) has announced that CEO Dr. Joseph Tucker will speak at the Microdose Presents Wonderland conference in Miami on November 8-9, 2021. Dr. Tucker is scheduled to participate in the Next-Generation Psychedelics panel on November 8 at 3:10 p.m. ET. Enveric is focused on developing innovative treatments for mental health and oncology using psychedelic-derived molecules and synthetic cannabinoids.
For details on attendance and meetings, interested parties can contact Microdose representatives or email KCSA Strategic Communications.
FAQ
What is the current stock price of Enveric Biosciences (ENVB)?
What is the market cap of Enveric Biosciences (ENVB)?
